Launch of generic creates uncertainty over Tecfidera future

20 August 2020
mylan_big

The first generic version of Biogen’s (Nasdaq: BIIB) main multiple sclerosis therapy, Tecfidera (dimethyl fumarate), is to launch in the USA.

Developed by Netherlands-incorporated generics firm Mylan (Nasdaq: MYL), the copycat drug has been subjected to intense legal efforts aimed at preventing the alternative from entering the market.

But after a string of legal defeats, Mylan  won a District Court judgment in June, paving the way for launch many years earlier than would otherwise have been possible.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics